Light Study Termination 'Positive' for Orexigen (OREX), Leerink Partners Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- L3Harris CEO steps down amid conduct review, shares drop
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
Buy This Dip in Orexigen (OREX), RBC Capital Says
May 13, 2015 6:35 AM EDTRBC Capital analyst Simos Simeonidis said with everyone pilling on against Orexigen Therapeutics (NASDAQ: OREX) they are buyers on this dip. The firm reiterated an Outperform rating and price target of $14.00.
Simeonidis said they spoke with CEO, Mike Narachi, who told them he "adamantly refutes the assertions that the company misled investors and patients." He was defiant in regards to today's news and defended Orexigen's handling of the LIGHT trial data. He told us that there was a data access plan in place, it was followed, and it actually had provisions for... More
UPDATE: Orexigen Therapeutics (OREX) and Takeda in Arbitration Over Terms of Deal
May 12, 2015 4:25 PM EDT(Updated - May 12, 2015 4:27 PM EDT)
Orexigen Therapeutics (NASDAQ: OREX) and Takeda are in arbitration on terms of collaboration, the company's CEO says in Bank of America presentation, according to CNBC's Meg Tirrell.
... More
Orexigen Therapeutics (OREX) Defended at Leerink
May 12, 2015 1:52 PM EDTOrexigen Therapeutics (NASDAQ: OREX) was defended a Leerink amid controversy after the company's Light trial was halted. Comments follow criticism in Forbes, which may have triggered a sell-off in the stock. In the view of analyst Paul Matteis, Light data showed what was expected -- safety and a positive trend.
"After OREX and Takeda announced the termination of the LIGHT study this morning, a Forbes article just disclosed data from the 50% interim analysis of the LIGHT study. Consistent with our... More
Orexigen Therapeutics (OREX) Mentioned Cautiously at Forbes
May 12, 2015 11:20 AM EDTOrexigen Therapeutics (NASDAQ: OREX) was mentioned cautiously in a Forbes article discussing results of its Light study of Contrave (link here).
... MoreTakeda, Orexigen Therapeutics (OREX) Announce Early Termination of Light Study
May 12, 2015 8:34 AM EDTTakeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Development Center Americas, Inc. (Takeda) and Orexigen Therapeutics, Inc. (Nasdaq: OREX) (Orexigen) have accepted the recommendation of the Executive Steering Committee (ESC), chaired by Dr. Steven Nissen of The Cleveland Clinic, for early termination of the Light Study, a... More
